Hereditary causes of kidney stones and chronic kidney disease

Pediatric Nephrology

Volumn 28, Issue 10, 2013, Pages 1923-1942

  Edvardsson, Vidar O ^a,b,c   Goldfarb, David S ^a,d   Lieske, John C ^a   Beara Lasic, Lada ^a,d   Anglani, Franca ^a,e   Milliner, Dawn S ^a   Palsson, Runolfur ^a,b,c  

^a MAYO CLINIC   (United States)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

2,8 dihydroxyadeninuria; Adenine phosphoribosyltransferase deficiency; Crystalline nephropathy; Cystinuria; Dent disease; Familial hypomagnesemia with hypercalciuria and nephrocalcinosis; Hereditary disorders; Kidney failure; Nephrocalcinosis; Nephrolithiasis; Primary hyperoxaluria

Indexed keywords

2,8 DIHYDROXYADENINE; ADENINE PHOSPHORIBOSYLTRANSFERASE; ADENOSINE PHOSPHATE; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM OXALATE; CALCIUM PHOSPHATE; CITRATE POTASSIUM; CITRATE SODIUM; CITRIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE; FEBUXOSTAT; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INOSINE PHOSPHATE; PENICILLAMINE; PLACEBO; PYRIDOXINE; THIAZIDE DIURETIC AGENT; TIOPRONIN; XANTHINE DEHYDROGENASE;

ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; AUTOSOMAL RECESSIVE DISORDER; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYSTINURIA; DENT DISEASE; EARLY DIAGNOSIS; EPIDEMIOLOGY; FAMILIAL HYPOMAGNESEMIA WITH HYPERCALCIURIA AND NEPHROCALCINOSIS; FLUID INTAKE; GENE SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CALCIFICATION; LABORATORY TEST; MEDICAL HISTORY; NEPHROLITHIASIS; OXALOSIS 1; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN RESTRICTION; REVIEW; TREATMENT OUTCOME;

ADENINE PHOSPHORIBOSYLTRANSFERASE; ANIMALS; CHILD; CYSTINURIA; DENT DISEASE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; HYPERCALCIURIA; HYPEROXALURIA, PRIMARY; KIDNEY CALCULI; METABOLISM, INBORN ERRORS; NEPHROCALCINOSIS; PHENOTYPE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL TUBULAR TRANSPORT, INBORN ERRORS; RISK FACTORS; UROLITHIASIS;

EID: 84883289608     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2329-z     Document Type: Review

References (128)

1. Sas DJ (2011) An update on the changing epidemiology and metabolic risk factors in pediatric kidney stone disease. Clin J Am Soc Nephrol 6:2062-2068
2. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63:1817-1823
3. Beara-Lasic L, Edvardsson V, Palsson R, Lieske J, Goldfarb D, Milliner D (2011) Genetic causes of kidney stones and kidney failure. Clin Rev Bone Miner Metab 10(6):1-18
4. Greenwood MC, Dillon MJ, Simmonds HA, Barratt TM, Pincott JR, Metreweli C (1982) Renal failure due to 2,8-dihydroxyadenine urolithiasis. Eur J Pediatr 138:346-349
5. Konrad M, Hou J, Weber S, Dotsch J, Kari JA, Seeman T, Kuwertz-Broking E, Peco-Antic A, Tasic V, Dittrich K, Alshaya HO, von Vigier RO, Gallati S, Goodenough DA, Schaller A (2008) CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 19:171-181
6. Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int 75:1264-1271
7. Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6:2069-2075
8. Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T (2001) Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland. Am J Kidney Dis 38:473-480
9. Bollee G, Dollinger C, Boutaud L, Guillemot D, Bensman A, Harambat J, Deteix P, Daudon M, Knebelmann B, Ceballos-Picot I (2010) Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol 21:679-688
10. Kelley WN, Levy RI, Rosenbloom FM, Henderson JF, Seegmiller JE (1968) Adenine phosphoribosyltransferase deficiency: a previously undescribed genetic defect in man. J Clin Invest 47:2281-2289
11. Sahota AS, Tischfield AJ, Kamatani N, Simmonds HA (2001) Adenine phosphoribosyltransferase deficiency and 2,8-dihydroxyadenine lithiasis. In: Scriver CRBA, Sly WS, Valle D, Vogelstein B, Childs B (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2571-2584
12. Broderick TP, Schaff DA, Bertino AM, Dush MK, Tischfield JA, Stambrook PJ (1987) Comparative anatomy of the human APRT gene and enzyme: nucleotide sequence divergence and conservation of a nonrandom CpG dinucleotide arrangement. Proc Natl Acad Sci U S A 84:3349-3353
13. Edvardsson VO, Palsson R, Sahota A (2012) Adenine Phosphoribosyltransferase Deficiency In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2010. Available at http://www.genetests.org
14. Kamatani N, Hakoda M, Otsuka S, Yoshikawa H, Kashiwazaki S (1992) Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients. J Clin Invest 90:130-135
15. Nasr SH, Sethi S, Cornell LD, Milliner DS, Boelkins M, Broviac J, Fidler ME (2010) Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. Nephrol Dial Transplant 25:1909-1915
16. Hidaka Y, Tarle SA, O'Toole TE, Kelley WN, Palella TD (1987) Nucleotide sequence of the human APRT gene. Nucleic Acids Res 15:9086
17. Sahota A, Chen J, Boyadjiev SA, Gault MH, Tischfield JA (1994) Missense mutation in the adenine phosphoribosyltransferase gene causing 2,8-dihydroxyadenine urolithiasis. Hum Mol Genet 3:817-818
18. Harambat J, Bollee G, Daudon M, Ceballos-Picot I, Bensman A (2012) Adenine phosphoribosyltransferase deficiency in children. Pediatr Nephrol 27:571-579
19. Debray H, Cartier P, Temstet A, Cendron J (1976) Child's urinary lithiasis revealing a complete deficit in adenine phosphoribosyl transferase. Pediatr Res 10:762-766
20. Chiba P, Zwiauer K, Muller MM (1988) Characterization of an adenine phosphoribosyltransferase deficiency. Clin Chim Acta 172:141-147
21. Cassidy MJ, McCulloch T, Fairbanks LD, Simmonds HA (2004) Diagnosis of adenine phosphoribosyltransferase deficiency as the underlying cause of renal failure in a renal transplant recipient. Nephrol Dial Transplant 19:736-738
22. Benedetto B, Madden R, Kurbanov A, Braden G, Freeman J, Lipkowitz GS (2001) Adenine phosphoribosyltransferase deficiency and renal allograft dysfunction. Am J Kidney Dis 37:E37
23. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52:916-923
24. Milliner DS, Murphy ME (1993) Urolithiasis in pediatric patients. Mayo Clin Proc 68:241-248
25. Chillaron J, Font-Llitjos M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacin M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6:424-434
26. Fernandez E, Carrascal M, Rousaud F, Abian J, Zorzano A, Palacin M, Chillaron J (2002) rBAT-b(0,+)AT heterodimer is the main apical reabsorption system for cystine in the kidney. Am J Physiol Renal Physiol 283:F540-548
27. Martens K, Jaeken J, Matthijs G, Creemers JW (2008) Multi-system disorder syndromes associated with cystinuria type I. Curr Mol Med 8:544-550
28. Dello Strologo L, Laurenzi C, Legato A, Pastore A (2007) Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr Nephrol 22:1869-1873
29. Lambert EH, Asplin JR, Herrell SD, Miller NL (2010) Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation. J Endourol 24:1179-1182
30. Worcester EM, Coe FL, Evan AP, Parks JH (2006) Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 97:1285-1290
31. Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ (2002) The impact of cystinuria on renal function. J Urol 168:27-30
32. Nakagawa Y, Coe FL (1999) A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. Clin Chim Acta 289:57-68
33. Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227-2235
34. Boutros M, Vicanek C, Rozen R, Goodyer P (2005) Transient neonatal cystinuria. Kidney Int 67:443-448
35. Goldfarb DS, Coe FL, Asplin JR (2006) Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 69:1041-1047
36. Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM (1984) The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol 22:273-278
37. Chow GK, Streem SB (1996) Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 156:1576-1578
38. Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164:1481-1485
39. Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS (2005) Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol 19:429-432
40. Pareek G, Steele TH, Nakada SY (2005) Urological intervention in patients with cystinuria is decreased with medical compliance. J Urol 174:2250-2252
41. Trinchieri A, Montanari E, Zanetti G, Lizzano R (2007) The impact of new technology in the treatment of cystine stones. Urol Res 35:129-132
42. Wrong OM, Norden AG, Feest TG (1994) Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. Q J Med 87:473-493
43. Lloyd SE, Gunther W, Pearce SH, Thomson A, Bianchi ML, Bosio M, Craig IW, Fisher SE, Scheinman SJ, Wrong O, Jentsch TJ, Thakker RV (1997) Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum Mol Genet 6:1233-1239
44. Thakker RV (2000) Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 57:787-793
45. Reinhart SC, Norden AG, Lapsley M, Thakker RV, Pang J, Moses AM, Frymoyer PA, Favus MJ, Hoepner JA, Scheinman SJ (1995) Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. J Am Soc Nephrol 5:1451-1461
46. Waldegger S, Jentsch TJ (2000) From tonus to tonicity: physiology of CLC chloride channels. J Am Soc Nephrol 11:1331-1339
47. Dutzler R (2004) Structural basis for ion conduction and gating in ClC chloride channels. FEBS Lett 564:229-233
48. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ (1998) ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A 95:8075-8080
49. Devuyst O, Christie PT, Courtoy PJ, Beauwens R, Thakker RV (1999) Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. Hum Mol Genet 8:247-257
50. Hara-Chikuma M, Wang Y, Guggino SE, Guggino WB, Verkman AS (2005) Impaired acidification in early endosomes of ClC-5 deficient proximal tubule. Biochem Biophys Res Commun 329:941-946
51. Picollo A, Pusch M (2005) Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436:420-423
52. Scheel O, Zdebik AA, Lourdel S, Jentsch TJ (2005) Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436:424-427
53. Novarino G, Weinert S, Rickheit G, Jentsch TJ (2010) Endosomal chloride-proton exchange rather than chloride conductance is crucial for renal endocytosis. Science 328:1398-1401
54. Friedrich T, Breiderhoff T, Jentsch TJ (1999) Mutational analysis demonstrates that ClC-4 and ClC-5 directly mediate plasma membrane currents. J Biol Chem 274:896-902
55. Hryciw DH, Ekberg J, Pollock CA, Poronnik P (2006) ClC-5: a chloride channel with multiple roles in renal tubular albumin uptake. Int J Biochem Cell Biol 38:1036-1042
56. --channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408:369-373
57. Wang SS, Devuyst O, Courtoy PJ, Wang XT, Wang H, Wang Y, Thakker RV, Guggino S, Guggino WB (2000) Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet 9:2937-2945
58. Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Verroust P, Leruth M, Guggino WB, Courtoy PJ (2003) Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci U S A 100:8472-8477
59. Silva IV, Cebotaru V, Wang H, Wang XT, Wang SS, Guo G, Devuyst O, Thakker RV, Guggino WB, Guggino SE (2003) The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J Bone Miner Res 18:615-623
60. Leheste JR, Melsen F, Wellner M, Jansen P, Schlichting U, Renner-Muller I, Andreassen TT, Wolf E, Bachmann S, Nykjaer A, Willnow TE (2003) Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J 17:247-249
61. Devuyst O, Thakker RV (2010) Dent's disease. Orphanet J Rare Dis 5:28
62. Claverie-Martin F, Ramos-Trujillo E, Garcia-Nieto V (2011) Dent's disease: clinical features and molecular basis. Pediatr Nephrol 26:693-704
63. Hoopes RR Jr, Raja KM, Koich A, Hueber P, Reid R, Knohl SJ, Scheinman SJ (2004) Evidence for genetic heterogeneity in Dent's disease. Kidney Int 65:1615-1620
64. Hoopes RR Jr, Shrimpton AE, Knohl SJ, Hueber P, Hoppe B, Matyus J, Simckes A, Tasic V, Toenshoff B, Suchy SF, Nussbaum RL, Scheinman SJ (2005) Dent Disease with mutations in OCRL1. Am J Hum Genet 76:260-267
65. Ghanekar Y, Lowe M (2005) Signalling for secretion. Nat Cell Biol 7:851-853
66. Choudhury R, Diao A, Zhang F, Eisenberg E, Saint-Pol A, Williams C, Konstantakopoulos A, Lucocq J, Johannes L, Rabouille C, Greene LE, Lowe M (2005) Lowe syndrome protein OCRL1 interacts with clathrin and regulates protein trafficking between endosomes and the trans-Golgi network. Mol Biol Cell 16:3467-3479
67. Tosetto E, Addis M, Caridi G, Meloni C, Emma F, Vergine G, Stringini G, Papalia T, Barbano G, Ghiggeri GM, Ruggeri L, Miglietti N, D Angelo A, Melis MA, Anglani F (2009) Locus heterogeneity of Dent's disease: OCRL1 and TMEM27 genes in patients with no CLCN5 mutations. Pediatr Nephrol 24:1967-1973
68. Hichri H, Rendu J, Monnier N, Coutton C, Dorseuil O, Poussou RV, Baujat G, Blanchard A, Nobili F, Ranchin B, Remesy M, Salomon R, Satre V, Lunardi J (2011) From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat 32:379-388
69. Copelovitch L, Nash MA, Kaplan BS (2007) Hypothesis: Dent disease is an underrecognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol 2:914-918
70. Frishberg Y, Dinour D, Belostotsky R, Becker-Cohen R, Rinat C, Feinstein S, Navon-Elkan P, Ben-Shalom E (2009) Dent's disease manifesting as focal glomerulosclerosis: is it the tip of the iceberg? Pediatr Nephrol 24:2369-2373
71. Bokenkamp A, Bockenhauer D, Cheong HI, Hoppe B, Tasic V, Unwin R, Ludwig M (2009) Dent-2 disease: a mild variant of Lowe syndrome. J Pediatr 155:94-99
72. Davey PG, Gosling P (1982) Beta 2-microglobulin instability in pathological urine. Clin Chem 28:1330-1333
73. Suzuki S, Suzuki J, Kume K, Yoshida K, Suyama H, Kawasaki Y, Nozawa R, Suzuki H, Fujiki T, Kamiyama S, Suzuki A (1999) Poor renal accumulation of 99mTc-DMSA in idiopathic tubular proteinuria. Nephron 81:49-54
74. Cebotaru V, Kaul S, Devuyst O, Cai H, Racusen L, Guggino WB, Guggino SE (2005) High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int 68:642-652
75. Michelis MF, Drash AL, Linarelli LG, De Rubertis FR, Davis BB (1972) Decreased bicarbonate threshold and renal magnesium wasting in a sibship with distal renal tubular acidosis. (Evaluation of the pathophysiological role of parathyroid hormone). Metabolism 21:905-920
76. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12:1872-1881
77. Faguer S, Chauveau D, Cintas P, Tack I, Cointault O, Rostaing L, Vargas-Poussou R, Ribes D (2011) Renal, ocular, and neuromuscular involvements in patients with CLDN19 mutations. Clin J Am Soc Nephrol 6:355-360
78. Godron A, Harambat J, Boccio V, Mensire A, May A, Rigothier C, Couzi L, Barrou B, Godin M, Chauveau D, Faguer S, Vallet M, Cochat P, Eckart P, Guest G, Guigonis V, Houillier P, Blanchard A, Jeunemaitre X, Vargas-Poussou R (2012) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin J Am Soc Nephrol 7:801-809
79. Rodriguez-Soriano J, Vallo A, Garcia-Fuentes M (1987) Hypomagnesaemia of hereditary renal origin. Pediatr Nephrol 1:465-472
80. 2+ resorption. Science 285:103-106
81. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, Nurnberg P, Weber S (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79:949-957
82. Li J, Ananthapanyasut W, Yu AS (2011) Claudins in renal physiology and disease. Pediatr Nephrol 26:2133-2142
83. Blanchard A, Jeunemaitre X, Coudol P, Dechaux M, Froissart M, May A, Demontis R, Fournier A, Paillard M, Houillier P (2001) Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int 59:2206-2215
84. Haisch L, Almeida JR, Abreu da Silva PR, Schlingmann KP, Konrad M (2011) The role of tight junctions in paracellular ion transport in the renal tubule: lessons learned from a rare inherited tubular disorder. Am J Kidney Dis 57:320-330
85. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y, Tsukita S (2002) Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. J Am Soc Nephrol 13:875-886
86. Hou J, Paul DL, Goodenough DA (2005) Paracellin-1 and the modulation of ion selectivity of tight junctions. J Cell Sci 118:5109-5118
87. Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Paul DL, Waldegger S, Goodenough DA (2008) Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 118:619-628
88. Hou J, Renigunta A, Gomes AS, Hou M, Paul DL, Waldegger S, Goodenough DA (2009) Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci U S A 106:15350-15355
89. Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleich M, Goodenough DA (2007) Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 282:17114-17122
90. 2+ transport function of Claudin-16. J Clin Invest 116:878-891
91. Hampson G, Konrad MA, Scoble J (2008) Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol 9:12
92. Stechman MJ, Loh NY, Thakker RV (2009) Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol 24:2321-2332
93. Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, Ortiz A, Rodicio JL (1995) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 47:1419-1425
94. Zimmermann B, Plank C, Konrad M, Stohr W, Gravou-Apostolatou C, Rascher W, Dotsch J (2006) Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant 21:2127-2132
95. Lieske JC, Spargo BH, Toback FG (1992) Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 148:1517-1519
96. Muda AO, Barsotti P, Rinaldi S, Rizzoni G, Faraggiana T (1997) Renal pathology in hyperoxaluria. In: Sessa A, Conte F, Meroni M, Battini G (eds) Hereditary kidney diseases. Karger, Basel, pp 160-166
97. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA (2003) Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 18:273-279
98. Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO (2006) Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 21:1075-1081
99. Coulter-Mackie MB (2005) Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype. Am J Nephrol 25:264-268
100. Danpure CJ (2005) Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 25:303-310
101. Milliner DS (2005) The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 25:154-160
102. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392-399
103. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289-2295
104. Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT (2011) Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One 6:e26021
105. Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704-1709
106. Monico CG, Rossetti S, Schwanz HA, Olson JB, Lundquist PA, Dawson DB, Harris PC, Milliner DS (2007) Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. J Amer Soc Nephrol 18:1905-1914
107. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS (2005) International registry for primary hyperoxaluria. Am J Nephrol 25:290-296
108. Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P (2010) Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77:443-449
109. Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker-Cohen R, Weismann I, Wanders RJ, Rumsby G, Roels F, Mandel H (2005) Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol 25:269-275
110. Hoppe B, Langman CB (2003) A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 18:986-991
111. Milliner D (2006) Treatment of the primary hyperoxalurias: a new chapter. Kidney Int 70:1198-1200
112. Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7:207-211
113. Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26:3609-3615
114. Monico CG, Olson JB, Milliner DS (2005) Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol 25:183-188
115. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642-1648
116. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493-2501
117. Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO (2003) One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 76:1458-1463
118. Silva M, Silva CH, Iulek J, Thiemann OH (2004) Three-dimensional structure of human adenine phosphoribosyltransferase and its relation to DHA-urolithiasis. Biochemistry 43:7663-7671
119. Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP (1997) Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr 131:252-257
120. Hoppe B, Kemper MJ (2010) Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 25:403-413
121. Rumsby G (1998) Experience in prenatal diagnosis of primary hyperoxaluria type 1. J Nephrol 11(Suppl 1):13-14
122. Barratt TM, Kasidas GP, Murdoch I, Rose GA (1991) Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 66:501-503
123. von Schnakenburg C, Byrd DJ, Latta K, Reusz GS, Graf D, Brodehl J (1994) Determination of oxalate excretion in spot urines of healthy children by ion chromatography. Eur J Clin Chem Clin Biochem 32:27-29
124. Gibbs DA, Watts RW (1969) The variation of urinary oxalate excretion with age. J Lab Clin Med 73:901-908
125. Morgenstern BZ, Milliner DS, Murphy ME, Simmons PS, Moyer TP, Wilson DM, Smith LH (1993) Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. J Pediatr 123:248-251
126. Campfield T, Braden G (1989) Urinary oxalate excretion by very low birth weight infants receiving parenteral nutrition. Pediatrics 84:860-863
127. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331:1553-1558
128. Morgan SH, Purkiss P, Watts RW, Mansell MA (1987) Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. Nephron 46:253-257